Hyperpolarized (HP) 13C

PreclinicalSmall molecule

Hyperpolarized (HP) 13C is one of 19 small molecule programs targeting Fatty Liver Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fatty Liver DiseaseActive, not recruiting

Fatty Liver DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Fatty Liver Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

1 2

Victoza

Novo Nordisk

Approved

1 3

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 4

Xifaxan

SSalix

Approved

1 5

Selincro

IIndivior Inc.

Approved

—6

Nexium

DDexcel Pharma Technologies Ltd.

Ozempic

4 8

Byetta

AstraZeneca

Phase 2

1 9

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 10

EGRIFTA WR

TTheratechnologies

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fatty Liver Disease1 trial

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

Unknown status·MMichael Ohliger, MD PhD··NCT06176079·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hyperpolarized (HP) 13C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized (HP) 13C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized (HP) 13C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Michael Ohliger, MD PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMichael Ohliger, MD PhD

Hyperpolarized (HP) 13C

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News